## ORIGINAL ARTICLE



# Presentation, tumour and treatment features in immigrant women from Arabic-speaking countries treated for breast cancer in Australia

Ghaith B. Heilat ,\* Meagan E. Brennan,† Kavitha Kanesalingam ,\* Nina Sriram,\* Farid Meybodi\* and James French\*

\*Westmead Breast Cancer Institute, Westmead Hospital, Sydney, New South Wales, Australia and

†Northern and Western Clinical Schools, The University of Sydney, Sydney, New South Wales, Australia

#### Key words

Arabic women, breast cancer.

#### Correspondence

Dr Ghaith B. Heilat, Westmead Breast Cancer Institute, Westmead Hospital, Hawkesbury Road and Darcy Road, Westmead, Sydney, NSW 2145, Australia. Email: g.heilat@yahoo.com

**G. B. Heilat** MD, MS, FEBS; **M. E. Brennan** FRACGP, FASBP, PhD; **K. Kanesalingam** MBChB, MRes, FRCS; **N. Sriram** MBBS; **F. Meybodi** MD, MS, FRACS; **J. French** MBBS, FRACS.

Accepted for publication 1 November 2019.

doi: 10.1111/ans.15596

#### **Abstract**

**Background:** Australia has a large population of immigrant women from Arabic-speaking countries. The aim of this study was to examine breast cancer tumour and surgical treatment features for women born in Arabic-speaking countries and compare them to women born in Australia and other countries. Another aim was to consider how this information can inform clinical care for this multicultural population.

**Methods:** This is a retrospective audit of an institutional breast cancer database. Demographic, tumour and surgical treatment data were extracted for the Arab women and compared to Australian-born women (comparison 1) and to women born in all other countries (comparison 2); chi-squared analysis was performed to test for differences between groups. **Results:** A total of 2086 cases with country of birth information were identified, of whom 139 women (6.7%) were born in Arabic-speaking countries, 894 (42.8%) were born in Australia and 1053 (50.4%) were born in other countries (71 nations). Arab women tended to be younger (P = 0.013), more disadvantaged (P < 0.001), were more likely to have symptomatic rather than screen-detected breast cancer (P < 0.001), had a higher rate of high grade (P = 0.021), HER2-positive (P = 0.025) breast cancer compared to Australian-born women or others. There was no difference in tumour (pT) stage, rate of breast conservation versus mastectomy, re-excision and contralateral prophylactic mastectomy between groups. Australian-born women were more likely to undergo breast reconstruction after mastectomy (P < 0.001); reconstruction rate was >29% in all groups.

**Conclusion:** Women born in Arabic-speaking countries were younger, more disadvantaged and showed more aggressive tumour features. This has implications for supportive care during treatment and survivorship.

#### Introduction

Breast cancer is the most common female cancer in most countries around the world, including Australia and Arab countries. <sup>1,2</sup> While there exists a large amount of data on breast cancer trends in the Australian population overall, there is less information available about immigrant women. Participation in the national screening programme is lower among the immigrant population in Australia compared to Australian-born women. <sup>3–5</sup> One of the major barriers to screening identified in the Arab-Australian population is the paradigm in which one must be sick to consult a health professional, so attending for preventive health reasons is not viewed as important. <sup>5</sup>

Western Sydney has the highest immigrant population in Australia, and it is increasing. Between 2011 and 2016, the overall

percentage of Western Sydney residents born in non-English-speaking countries increased by 21.3%. Currently, 40.4% of the population of Western Sydney was born overseas. Forty-five percent speak a language other than English at home, a rate double the New South Wales state average.<sup>6</sup>

Immigration from Arab countries is increasing around the world. It is important to understand illness in this population in order to support women and their families in a culturally appropriate manner.

The aim of this study was to describe breast cancer presentation, tumour and treatment characteristics in women treated in Western Sydney and born in Arab countries, and to compare these to women born in Australia or in other (non-Arab) countries. 2 Heilat et al.

#### **Methods**

This was a retrospective audit of the prospectively maintained institutional database. The database was searched to identify cases who met the eligibility criteria: female, aged over 18 years, treated for ductal carcinoma in situ (DCIS) or invasive breast cancer and born in a country with Arabic as a national language (Algeria, Bahrain, Egypt, Iraq, Jordan, Kuwait, Lebanon, Libya, Mauritania, Morocco, Oman, Palestine, Qatar, Saudi Arabia, Sudan, Syria, Tunisia, United Arab Emirates and Yemen). Cases were excluded when key pathological factors such as tumour type, size and grade were missing.

Data were extracted for patient demographics (including age, country of birth, religion, marital status and postcode of residence), tumour factors (including method of detection, histological type, size, grade and receptor status) and surgical treatment factors (including breast conservation versus mastectomy, re-excision, breast reconstruction and contralateral prophylactic surgery). The same data were collected for women born in Australia (first comparison group, referred to as 'Australian-born') or born outside Australia in non-Arab countries (second comparison group, referred to as 'other') and treated during the same time period.

Area of disadvantage decile was determined using Australian government postcode tables based on census data.<sup>7</sup>

Analysis was conducted using SPSS Statistics Version 24 (IBM Corp., Armonk, NY, USA). Descriptive statistics were used to

summarize each factor in each of the three groups. Chi-squared analysis was used to evaluate differences between groups. A *P*-value of ≤0.05 was considered significant. Institutional ethics approval was obtained (Western Sydney HREC, 2019/ETH10761).

#### Results

The search of the database resulted in 2086 eligible cases (breast malignancy, with country of birth information available). These were treated between 2011 and 2017. There were 2084 cases of unilateral breast cancer (99.8%) and two bilateral cases (0.2%). In addition, there was information about three benign contralateral breast procedures performed on patients with unilateral cancer.

Country of birth is shown in Table S1. One hundred and thirtynine women (6.7%) were born in Arabic-speaking countries, 894 (42.8%) were born in Australia and 1053 (50.4%) were born in other countries. Among women born in other countries, 71 different nations were represented.

#### **Demographics**

Demographic data are shown in Tables 1 and S2. Most of the variables examined showed highly statistically significant differences between the three groups. The mean age of the population overall was 58.6 years (median 58.5; range 20–94) and there was no statistically significant difference in the mean or median age between

**Table 1** Demographic data for women born in Arab countries, Australia and other countries (n = 2086)

	Arab coun (n = 139		Australi (n = 894		Other non-A country ( $n = \frac{1}{2}$		Total		$\chi^2$ value	<i>P</i> -value
	n	%	n	%	n	%	n	%		
Age, years										
Median	57.4		58.9		58.4		58.5			0.069
Mean (SD)	56.7 (10.32)		59.1 (12.45)		58.4 (11.76)		58.6 (11.93)			0.069
Age group										
20–35	2	1.4	30	3.4	22	2.1	54	2.6		
36–50	39	28.1	195	21.8	250	23.7	484	23.2		
51–65	70	50.4	380	42.5	487	46.2	934	44.9		
66–80	27	19.4	247	26.7	263	25.0	537	25.7		
>80	1	0.7	42	4.7	32	3.0	75	3.6		
Total	139	100.0	894	100.0	1054	100.0	2087	100.0	19.300	0.013
Preferred language										
Arabic	57	41.0	5	0.6	0	0.0	62	3.0		
English	72	51.8	886	99.1	702	66.7	1660	79.6		
Other	8	5.8	3	0.3	337	32.0	348	16.7		
Unknown	2	1.4	0	0.0	14	1.3	16	0.8		
Total	139	100.0	894	100.0	1053	100.0	2074	100.0	1117.078	< 0.001
Area of disadvantage	decile†									
1–2	68	48.9	178	19.9	231	22.9	477	22.9		
3–4	17	13.8	124	13.8	141	13.4	282	13.6		
5–6	14	10.1	177	19.8	161	15.3	352	16.9		
7–8	22	15.8	213	23.9	249	23.7	484	23.2		
9–10	18	12.9	200	22.4	271	25.7	489	23.4		
Unknown	0	0.0	2	0.2	0	0.0	2	0.1		
Total	139	100.0	894	100.0	1053	100.0	2086	100.0	82.531	< 0.001
Menopausal status										
Pre-menopausal	37	26.6	179	20.0	224	22.2	440	22.1		
Peri-menopausal	19	13.7	85	9.5	77	7.3	181	8.7		
Post-menopausal	74	53.2	591	66.1	706	67.0	1371	65.7		
Unknown	9	6.5	39	4.4	47	4.5	95	4.6		
Total	139	100.0	894	100.0	1053	100.0	2086	100.0	12.996	0.012

 ${\ \ }^{\dagger} Area \ of \ disadvantage \ determined \ by \ residential \ postcode. \ A \ lower \ number \ indicates \ higher \ disadvantage$ 

groups. However, when age analysis was conducted by age group, a higher proportion of women born in Arabic-speaking countries were in the younger age brackets than women in the other groups. Nearly 80% of Arab women were under the age of 65 years compared to 68% of Australian-born and 72% of others (P = 0.013). Arab women were less likely to be post-menopausal than women in the other groups (P = 0.012).

Women born in Arabic-speaking countries were significantly more likely to report Arabic to be their preferred language (P < 0.001). Of note, one-third of non-Arab, non-Australian women also reported having a preferred language other than English. Arab women were more likely to report having a religion (more than 96%) compared to the other groups where 'no religion' or 'atheist' or 'agnostic' were reported (Australian-born women 14% and other women 16%). Most Arab women were Christian (72%), predominately composed of the large Christian population born in Lebanon. Twenty-four percent of Arab women were Muslim. Arab women were significantly more likely than others to be married (P < 0.001).

Arab women were significantly more likely to live in a disadvantaged area (P < 0.001), with nearly half having a residential post-code in the lower two deciles (1–2) compared to 20% of Australian-born and 22% of other women. The top two deciles (9–10) contained 13% of Arab women compared to 22% of Australian-born women and 26% of others.

Arab women were more likely to be obese (P < 0.001) and less likely to have ever used the oral contraceptive pill (P < 0.001). They were less likely than Australian-born women to report a family history of breast cancer (37% versus 48%) but more likely than others (33.4%, P < 0.001).

#### **Tumour characteristics**

Tumour features are shown in Table 2. Australian-born women were significantly more likely to have their cancer detected by screening than Arab or other women (P < 0.001). There was no difference in tumour palpability at first treatment assessment.

Arab women were more likely to have DCIS than invasive cancer compared to the other two groups (19% versus 12% and 15%, P = 0.048). There was no significant difference in size or grade of DCIS. For invasive cancer, however, Arabic women were significantly more likely to have higher grade tumours (P = 0.021) than Australian-born and other women, and tumours were more likely to be larger although this result did not quite reach statistical significance (P = 0.053). There was no difference in oestrogen (ER) or progesterone (PR) receptor expression; however, Arab women were more likely than the other two groups to have a tumour that was human epidermal growth factor receptor 2 (HER2)-positive (P = 0.025).

#### **Surgical treatment factors**

Treatment factors are shown in Table 3. There was no difference between rates of breast conservation versus mastectomy (P = 0.080) or in re-excision rates (P = 0.391). When mastectomy was performed, Australian-born women were significantly more likely than Arab or other women to have immediate breast

reconstruction (48% versus 30% and 38%, P < 0.001). Arab women were significantly less likely than Australian-born and other women to choose contralateral prophylactic mastectomy (2% versus 22% and 15%, P < 0.001). When contralateral prophylactic mastectomy was chosen, there was no significant difference in immediate breast reconstruction rates between the three groups (P = 0.095).

### Arabic-speaking versus English-speaking women

Further analysis was performed to test for differences between women born in Arab countries whose preferred language was Arabic compared to those born in Arab countries whose preferred language was English. We found that Arabic-speaking women had statistically significantly more disadvantages. Of Arabic-speaking women, 66.7% were in the bracket of greatest disadvantage compared to 38.9% of English-speaking women (P < 0.001). There were no differences in any other variables, including body mass index; marital status; family history; method of detection; palpability; type of malignancy (DCIS versus invasive cancer); ER, PR or HER2 status; initial operation; and post-mastectomy breast reconstruction.

#### **Discussion**

This study explored the method of breast cancer diagnosis, tumour characteristics and surgical treatment factors in a population of migrant women from Arabic-speaking countries living in an extremely diverse community in Australia. In addition to Australia and nine Arabic-speaking countries, there were 71 countries of birth represented in women presenting for breast cancer treatment at this major referral centre. This allows a unique study of a very diverse multicultural population.

The Arab women fell into significantly younger age brackets, had a higher body mass index and were significantly more disadvantaged than the Australian-born and other groups. The younger age finding in this study is similar to findings from previous studies also reporting that breast cancer occurs at a younger age in women in Arabic-speaking countries. The age at diagnosis was found to be 8–12 years younger for Kurdish women living in the USA than American-born women. This has not been fully explained, but is consistent with the observation that breast cancer incidence is particularly low among women in the Middle East, where the incidence decreases with age rather than increasing as it does in Western countries.

The Arab population was less likely to have a screen-detected breast cancer and more likely to be symptomatic. This aligns with data from the population screening programme that shows that migrant women have a lower rate of attendance for routine mammography. BreastScreen participation is significantly lower among the migrant population in Australia compared to Australian-born women. The participation rate of women who speak a language other than English at home is <49%, compared to around 55% in English-speaking women. Screening rates in women from Arabic-speaking countries is one of the lowest among migrant women in Australia. However, women born in Arab countries had a higher rate of DCIS than the other groups, which would not be

4 Heilat et al.

**Table 2** Tumour characteristics for malignancy in women born in Arab countries, Australia and other countries (n = 2086)

Unwindulated brease cancer Unwindulated brease c		Arab country		Australia		Other non-Arab country		Total		$\chi^2$ value	<i>P</i> -value
Unitedural cancer 139 100.0 893 99.8 1062 99.8 2094 99.8   September 139 100.0 893 100.0 10.2 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0							•			χ value	7 Value
Unlike part											
Bilateral synchronous cenery		120	100.0	902	00.0	1052	00.0	2004	00.0		
Unknown											
Total	•										
Screen-defected										0.317	0.853
Symptomatic   69   49.6   378   42.3   511   48.5   59.8   49.9   100.0   10											
Unknown	Screen-detected	64		489	54.7		46.9				
Total											
Pelpable   117										10.0001	.0.001
Palpable   117		139	100.0	894	100.0	1053	100.0	2086	100.0	10.9991	<0.001
None place   16		117	84 2	738	82 6	890	84.5	1745	83.7		
Total 19, 100, 894 100, 1053 100, 2086 100, 4.552 0.03 Type of malignaney DCIS Invasive cancer 112 813, 774 866 876 83.2 1762 84.5 Unknown 1 1, 1.3 12 1.3 19 1.8 32 1.5 Total 199 100, 894 100, 1053 100, 2086 100, 6.68  Grade of DCIS  Low Intermediate 8 30.8 22 20.4 39 24.7 69 23.6 High 12 46.2 70, 64.8 90 57.0 172 58.9 Unknown 3 11.5 10 9.3 12 7.6 25 8.6 Unknown 3 11.5 10 9.3 12 7.6 25 8.6 Unknown 3 11.5 10 9.3 12 7.6 25 8.6 Unknown 3 11.5 10 9.3 12 7.6 25 8.6 Unknown 3 11.5 10 9.3 12 7.6 25 8.6 Unknown 3 11.5 10 9.3 12 7.6 25 8.6 Unknown 17 66.4 53 49.1 86 54.4 156 53.4 20-80 mm 6 23.1 40 37.0 53 33.5 99 33.9 250 mm 17 66.4 53 49.1 80, 59.2 100, 10.3 Unknown 3 11.5 14 13.0 19 12.0 36 12.3 Unknown 3 11.5 14 13.0 19 12.0 36 12.3 Unknown 3 11.5 14 13.0 19 12.0 36 12.3 Unknown 3 11.5 14 13.0 19 12.0 36 12.3 Unknown 13 7 66.4 53 49.1 10.0 188 100, 288 100, 288 100, 40.1 Unknown 3 11.5 14 13.0 19 12.0 36 12.3 Unknown 13 17.5 65.7 56 73.1 8.8 39.5 17.2 9.8 Unknown 13 17.5 85 75.9 566 73.1 640 73.1 1291 73.3 Invasive lobular 13 11.6 76 9.8 83 9.5 17.2 9.8 Invasive lobular 13 11.6 76 9.8 83 9.5 17.2 9.8 Invasive lobular 1 10.9 15 1.9 16 18 18 32 1.8 Medullary 0 0 0.0 2 0.3 3 0.0 0.0 2 0.1 Micelly 9 3 2.7 33 4.3 35 4.0 71 4.0 4.4 Mucinous 2 1 1.8 23 3.0 28 3.3 56 4.0 71 4.0 Unknown 1 10 9 10 13 3 13 1.5 23 1.3 Unknown 1 10 9 10 13 3 13 1.5 23 1.3 Unknown 2 2 1.8 23 3.0 28 3.3 56 4.0 71 4.0 Unknown 2 2 1.8 23 3.0 28 3.3 56 2.3 Unknown 3 2.7 77 22 2.2 2.2 2.2 4 6.2 3.6 Unknown 3 2.7 77 22 2.2 2.2 4 6.2 3.6 Unknown 3 2.7 77 2.2 2.2 2.2 4 6.2 3.6 Unknown 3 2.7 77 2.2 2.2 2.2 4 6.2 3.6 Unknown 3 2.7 77 2.2 2.2 2.2 4 6.2 3.6 Unknown 3 2.7 77 2.2 2.2 2.2 4 6.2 3.6 Unknown 3 2.7 77 2.2 2.2 2.2 4 6.2 3.6 Unknown 3 2.7 77 2.2 2.2 2.2 4.6 Unknown 3 2.7 17 2.2 2.2 2.2 4.6 Unknown 3 2.7 17 2.2 2.2 2.2 4.6 Unknown 3 2.7 17 2.2 2.2 2.2 4.6 Unknown 2 2 18.0 45 58.8 64 7.3 118 67.0 Unknown 2 2 18.0 45 58.8 64 7.3 118 67.0 Unknown 2 2 18.0 45 58.8 64 7.3 118 67.0 Unknown 2 2 18.0 45 58.8 64 7.3 118 66 15.1 Unknown 2 2 18.0 45 59.2 76.9 6	•										
Type of malignancy   Section   Color	Unknown	6	4.3	41	4.6	61	5.8				
DCIS		139	100.0	894	100.0	1053	100.0	2086	100.0	4.552	0.103
Invasive cancer											
Unknown											
Total   139   100.0   894   100.0   1053   100.0   2086   100.0   6.068   0.048											
Crow										6.068	0.048
Low		100	100.0	554	100.0	1000	100.0	2000	100.0	3.000	0.040
High   12		3		6	5.6		10.8	26	8.9		
Unknown											
Total   26	•										
Size of DCIS											
C20 mm		26	100.0	108	100.0	158	100.0	292	100.0	4.223	0.377
2-0-0 mm		17	65.4	53	<i>1</i> 9.1	86	54.4	156	53 <i>1</i>		
No.											
Total											
Histology of invasive cancer   Ductal NST   85   75.9   566   73.1   640   73.1   1291   73.3   73.5   73	Unknown	3	11.5	14	13.0	19	12.0	36	12.3		
Ductal NST		26	100.0	108	100.0	158	100.0	292	100.0	4.017	0.404
Invasive lobular	0,	0.5	== 0		70.4			4004	70.0		
Tubular											
Medullary         0         0.0         2         0.3         0         0.0         2         0.1           Metaplastic         1         0.9         2         0.3         3         0.3         6         0.3           Mixed type         3         2.7         33         4.3         35         4.0         71         4.0           Papillary         1         0.9         17         2.2         24         2.8         42         2.4           Mucinous         2         1.8         23         3.0         29         3.3         54         3.1           Other         5         4.5         30         3.9         33         3.8         68         3.9           Unknown         1         0.9         10         1.3         13         1.5         23         1.3           Total         12         10.0         774         100.0         876         100.0         162         10.0         8.161         0.944           Grade 1         16         14.3         182         23.5         156         17.8         354         20.1         362         362         38.1         361         41.2         20.1 </td <td></td>											
Metaplastic         1         0.9         2         0.3         3         0.3         6         0.3           Mixed type         3         2.7         33         4.3         35         4.0         71         4.0           Papillary         1         0.9         17         2.2         24         2.8         42         2.4           Mucinous         2         1.8         23         3.0         29         3.3         54         3.1           Other         5         4.5         30         3.9         33         3.8         68         3.9           Unknown         1         0.9         10         1.3         13         1.5         23         1.3           Total         112         100.0         774         100.0         876         100.0         1762         100.0         8.161         0.944           Grade 1         112         100.0         774         100.0         876         100.0         1762         100.0         8.161         0.944           Grade 2         45         40.2         295         38.1         361         41.2         701         39.8         36.1         41.2         701<											
Papillary	•										
Mucinous         2         1.8         23         3.0         29         3.3         54         3.1           Other         5         4.5         30         3.9         33         3.8         68         3.9           Unknown         1         0.99         10         1.3         13         1.5         23         1.3           Total         112         100.0         774         100.0         876         100.0         1762         100.0         8.161         0.944           Grade 1         16         14.3         182         23.5         156         17.8         354         20.1         Gade 2         45         40.2         295         38.1         361         41.2         701         39.8         Grade 3         48         42.9         280         36.2         334         38.1         662         37.6         Unknown         3         2.7         17         2.2         25         2.9         45         2.6         Total         11.602         0.021         32.2         334         38.1         662         37.6         37.6         33.2         33.2         334         38.1         662         37.6         36.2         34.8	Mixed type	3	2.7	33	4.3	35	4.0	71	4.0		
Other Unknown         5         4.5         30         3.9         33         3.8         68         3.9           Unknown         1         0.9         10         1.3         13         1.5         23         1.3           Total         112         100.0         774         100.0         876         100.0         1762         10.0         8.161         0.944           Grade of invasive cancer         676de 1         16         14.3         182         23.5         156         17.8         354         20.1         20.1         39.8         673         40.2         295         38.1         361         41.2         701         39.8         662         37.6         10.0         10.0         30.2         334         38.1         662         37.6         37.6         10.0         10.0         11.602         37.6         10.0         10.0         17.0         11.602         30.2         334         38.1         662         37.6         37.6         10.0         11.602         37.6         10.0         10.0         17.6         10.0         11.602         0.021         35.2         13.0         48         2.6         37.6         10.0         11.602         30											
Unknown											
Total         112         100.0         774         100.0         876         100.0         1762         100.0         8.161         0.944           Grade of invasive cancer         Grade 1         16         14.3         182         23.5         156         17.8         354         20.1         20.1         17.8         361         41.2         701         39.8         20.1											
Grade of invasive cancer         Grade 1         16         14.3         182         23.5         156         17.8         354         20.1           Grade 2         45         40.2         295         38.1         361         41.2         701         39.8           Grade 3         48         42.9         280         36.2         334         38.1         662         37.6           Unknown         3         2.7         17         2.2         25         2.9         45         2.6           Total         112         100.0         774         100.0         876         100.0         1762         100.0         11.602         0.021           Size of invasive cancer         pT1         48         42.9         429         55.4         489         55.8         968         55.3           pT2         54         48.2         295         38.1         315         36.0         666         38.0           pT3         9         8.0         45         5.8         64         7.3         118         6.7           Unknown         1         180.0         74         100.0         876         100.0         1762         100.0 <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>Q 161</td> <td>0.044</td>										Q 161	0.044
Grade 1         16         14.3         182         23.5         156         17.8         354         20.1           Grade 2         45         40.2         295         38.1         361         41.2         701         39.8           Grade 3         48         42.9         280         36.2         334         38.1         662         37.6           Unknown         3         2.7         17         2.2         25         2.9         45         2.6           Total         112         100.0         774         100.0         876         100.0         1762         100.0         11.602         0.021           Size of invasive cancer         8         42.9         42.9         55.4         489         55.8         968         55.3         55.3         57         57         97         48.2         295         38.1         315         36.0         666         38.0         98         45.3         38.1         315         36.0         666         38.0         98         48.2         295         38.1         315         36.0         666         38.0         99         48.0         48.2         295         38.1         100.0         73.2		112	100.0	774	100.0	070	100.0	1702	100.0	0.101	0.044
Grade 3         48         42.9         280         36.2         334         38.1         662         37.6           Unknown         3         2.7         17         2.2         25         2.9         45         2.6           Total         112         100.0         774         100.0         876         100.0         1762         100.0         11.602         0.021           Size of invasive cancer         pT1         48         42.9         429         55.4         489         55.8         968         55.3           pT2         54         48.2         295         38.1         315         36.0         666         38.0           pT3         9         8.0         45         5.8         64         7.3         118         6.7           Unknown         2         180.0         5         0.6         8         0.9         14         0.8           Total         112         100.0         774         100.0         876         100.0         1762         100.0         9.33         0.053           ER status of invasive cancer         94         83.9         624         80.6         722         82.4         1440		16	14.3	182	23.5	156	17.8	354	20.1		
Unknown         3         2.7         17         2.2         25         2.9         45         2.6           Total         112         100.0         774         100.0         876         100.0         1762         100.0         11.602         0.021           Size of invasive cancer         PT1         48         42.9         429         55.4         489         55.8         968         55.3         55.3         57.3         <	Grade 2	45	40.2	295	38.1	361	41.2	701	39.8		
Total         112         100.0         774         100.0         876         100.0         1762         100.0         11.602         0.021           Size of invasive cancer         pT1         48         42.9         429         55.4         489         55.8         968         55.3           pT2         54         48.2         295         38.1         315         36.0         666         38.0           pT3         9         8.0         45         5.8         64         7.3         118         6.7           Unknown         2         180.0         5         0.6         8         0.9         14         0.8           Total         112         100.0         774         100.0         876         100.0         1762         100.0         9.33         0.053           ER status of invasive cancer         94         83.9         624         80.6         722         82.4         1440         81.7         1450         1450         1450         1450         1450         1450         1450         1450         1450         1450         1450         1450         1450         1450         1450         1450         1450         1450         1450<											
Size of invasive cancer   PT1										44.600	0.004
pT1         48         42.9         429         55.4         489         55.8         968         55.3           pT2         54         48.2         295         38.1         315         36.0         666         38.0           pT3         9         8.0         45         5.8         64         7.3         118         6.7           Unknown         2         180.0         5         0.6         8         0.9         14         0.8           Total         112         100.0         774         100.0         876         100.0         1762         100.0         9.33         0.053           ER status of invasive cancer         94         83.9         624         80.6         722         82.4         1440         81.7         81.7         9.7         9.0         9.0         9.33         0.053           ER status of invasive cancer         94         83.9         624         80.6         722         82.4         1440         81.7         81.7         9.0         9.0         9.0         9.0         9.0         9.0         9.0         9.0         9.0         9.0         9.0         9.0         9.0         9.0         9.0         9.0<		112	100.0	/74	100.0	876	100.0	1762	100.0	11.602	0.021
pT2         54         48.2         295         38.1         315         36.0         666         38.0           pT3         9         8.0         45         5.8         64         7.3         118         6.7           Unknown         2         180.0         5         0.6         8         0.9         14         0.8           Total         112         100.0         774         100.0         876         100.0         1762         100.0         9.33         0.053           ER status of invasive cancer         94         83.9         624         80.6         722         82.4         1440         81.7           Negative         16         14.3         123         15.9         127         14.5         266         15.1           Unknown         2         1.8         27         3.5         27         3.1         56         3.2           Total         112         100.0         774         100.0         876         100.0         1762         100.0         0.818         0.664           PR status of invasive cancer         70         674         76.9         1356         77.0           Negative         20		//Ω	/2 Q	//20	55.4	180	55 Q	969	55 S		
pT3         9         8.0         45         5.8         64         7.3         118         6.7           Unknown         2         180.0         5         0.6         8         0.9         14         0.8           Total         112         100.0         774         100.0         876         100.0         1762         100.0         9.33         0.053           ER status of invasive cancer         94         83.9         624         80.6         722         82.4         1440         81.7 <td>•</td> <td></td>	•										
Unknown         2         180.0         5         0.6         8         0.9         14         0.8           Total         112         100.0         774         100.0         876         100.0         1762         100.0         9.33         0.053           ER status of invasive cancer         Positive         94         83.9         624         80.6         722         82.4         1440         81.7         Negative         16         14.3         123         15.9         127         14.5         266         15.1	•										
ER status of invasive cancer  Positive 94 83.9 624 80.6 722 82.4 1440 81.7  Negative 16 14.3 123 15.9 127 14.5 266 15.1  Unknown 2 1.8 27 3.5 27 3.1 56 3.2  Total 112 100.0 774 100.0 876 100.0 1762 100.0 0.818 0.664  PR status of invasive cancer  Positive 90 80.4 592 76.9 674 76.9 1356 77.0  Negative 20 17.9 153 19.8 172 19.6 345 19.6  Unknown 2 1.8 29 3.7 30 3.4 61 3.5						8					
Positive         94         83.9         624         80.6         722         82.4         1440         81.7           Negative         16         14.3         123         15.9         127         14.5         266         15.1           Unknown         2         1.8         27         3.5         27         3.1         56         3.2           Total         112         100.0         774         100.0         876         100.0         1762         100.0         0.818         0.664           PR status of invasive cancer         90         80.4         592         76.9         674         76.9         1356         77.0           Negative         20         17.9         153         19.8         172         19.6         345         19.6           Unknown         2         1.8         29         3.7         30         3.4         61         3.5		112	100.0	774	100.0	876	100.0	1762	100.0	9.33	0.053
Negative         16         14.3         123         15.9         127         14.5         266         15.1           Unknown         2         1.8         27         3.5         27         3.1         56         3.2           Total         112         100.0         774         100.0         876         100.0         1762         100.0         0.818         0.664           PR status of invasive cancer         Positive         90         80.4         592         76.9         674         76.9         1356         77.0           Negative         20         17.9         153         19.8         172         19.6         345         19.6           Unknown         2         1.8         29         3.7         30         3.4         61         3.5		•			60.	=05	22		a		
Unknown         2         1.8         27         3.5         27         3.1         56         3.2           Total         112         100.0         774         100.0         876         100.0         1762         100.0         0.818         0.664           PR status of invasive cancer         Positive         90         80.4         592         76.9         674         76.9         1356         77.0           Negative         20         17.9         153         19.8         172         19.6         345         19.6           Unknown         2         1.8         29         3.7         30         3.4         61         3.5											
Total         112         100.0         774         100.0         876         100.0         1762         100.0         0.818         0.664           PR status of invasive cancer         Positive         90         80.4         592         76.9         674         76.9         1356         77.0           Negative         20         17.9         153         19.8         172         19.6         345         19.6           Unknown         2         1.8         29         3.7         30         3.4         61         3.5	•										
PR status of invasive cancer  Positive 90 80.4 592 76.9 674 76.9 1356 77.0  Negative 20 17.9 153 19.8 172 19.6 345 19.6  Unknown 2 1.8 29 3.7 30 3.4 61 3.5										0.818	0.664
Positive     90     80.4     592     76.9     674     76.9     1356     77.0       Negative     20     17.9     153     19.8     172     19.6     345     19.6       Unknown     2     1.8     29     3.7     30     3.4     61     3.5		112	100.0	,,,	100.0	370	100.0	1702	100.0	0.010	0.004
Negative         20         17.9         153         19.8         172         19.6         345         19.6           Unknown         2         1.8         29         3.7         30         3.4         61         3.5		90	80.4	592	76.9	674	76.9	1356	77.0		
Total 112 100.0 774 100.0 876 100.0 1762 100.0 0.153 0.927											
	Total	112	100.0	774	100.0	876	100.0	1762	100.0	0.153	0.927

Table 2 Continued

	Arab country		Australia		Other non-Arab country		Total		$\chi^2$ value	<i>P</i> -value
	n	%	n	%	n	%	n	%		
HER2 status of invasive cancer										
Positive	21	18.8	74	9.6	100	11.4	195	11.1		
Negative	83	74.1	608	78.6	682	77.9	1373	77.9		
Unknown	8	7.1	92	11.9	94	10.7	194	11.0		
Total	112	100.0	774	100.0	876	100.0	1762	100.0	7.401	0.025
Multifocal invasive cancer										
Yes	25	22.3	179	23.1	197	22.5	401	22.8		
No	72	64.3	549	70.0	633	72.3	1254	71.2		
Unknown	15	13.4	46	5.9	46	5.3	107	6.1		
Total	112	100.0	774	100.0	876	100.0	1762	100.0	0.265	0.876
Multifocality, all tumours										
Yes	30	21.6	199	22.3	224	21.3	453	21.7		
No	91	65.5	643	71.9	770	73.1	1504	72.1		
Unknown	18	12.9	52	5.8	59	5.6	129	6.2		
Total	139	100.0	894	100.0	1053	100.0	2086	100.0	0.483	0.786

DCIS, ductal carcinoma in situ; ER, oestrogen; HER2, human epidermal growth factor receptor 2; NST, no special type; PR, progesterone.

**Table 3** Surgical treatment factors for malignancy in women born in Arab countries, Australia and other countries (n = 2086)

Initial breast conservation type   Standard wide local excision   98   95.1   558   88.9   633   90.4   1289   90.3		Arab country		Australia		Other non-Arab country		Total		$\chi^2$ value	<i>P</i> -value
Breast conservation   103   74.1   628   70.2   700   66.5   1431   68.6		n	%	n	%	n	%	n	%		
Mastectomy         36         25.9         265         29.6         348         33.0         649         31.1           Unknown         0         0.0         1         0.1         5         0.5         6         0.3           Total         139         100.0         894         100.0         1053         100.0         2086         100.0         5.045         0.0           Initial breast conservation type         Standard wide local excision         98         95.1         558         88.9         633         90.4         1289         90.3           Therapeutic mammaplasty         6         5.8         65         10.2         61         8.7         132         9.2           Wide excision and local flap         0         0.0         2         0.3         2         0.3         3         0.2           Total         103         100.0         628         100.0         700         100.0         1431         100.0         3.322         0.5           Re-excision after breast conservation         21         20.4         113         18.0         124         17.7         258         18.0           No         82         79.6         506         80.7	Initial operation										
Unknown	Breast conservation	103	74.1	628	70.2	700	66.5	1431	68.6		
Total	Mastectomy	36	25.9	265	29.6	348	33.0	649	31.1		
Initial breast conservation type   Standard wide local excision   98   95.1   558   88.9   633   90.4   1289   90.3	Unknown	0	0.0	1	0.1	5	0.5	6	0.3		
Standard wide local excision   98   95.1   558   88.9   633   90.4   1289   90.3	Total	139	100.0	894	100.0	1053	100.0	2086	100.0	5.045	0.08
Standard wide local excision   98   95.1   558   88.9   633   90.4   1289   90.3     Therapeutic manmaplasty   6   5.8   65   10.2   61   8.7   132   9.2     Wide excision and local flap   0   0.0   3   0.5   4   0.6   7   0.5     Unknown   0   0.0   2   0.3   2   0.3   3   0.2     Total   103   100.0   628   100.0   700   100.0   1431   100.0   3.322   0.5     Re-excision after breast conservation     Yes   21   20.4   113   18.0   124   17.7   258   18.0     No   82   79.6   506   80.7   567   80.9   1155   80.7     Unknown   0   0.0   8   1.3   10   1.4   18   1.3     Total   103   100.0   627   100.0   701   100.0   1431   100.0   0.391   0.5     Final operation     Breast conservation   95   68.3   579   64.8   648   61.5   1322   63.5     Mastectomy   44   31.7   314   35.1   400   38.0   758   36.5     Unknown   0   0.0   0   1   0.1   5   0.5   6   0.3     Total   139   100.0   894   100.0   1053   100.0   2086   100.0   3.615   0.1     Reconstruction after mastectomy     No immediate reconstruction   31   70.5   165   52.2   271   67.8   467   61.7     Immediate reconstruction   31   29.5   151   47.8   130   32.2   294   38.3     Unknown   0   0.0   0   0.0   0.0   0.0   0.0   0.0     Total   44   100.0   316   100.0   401   100.0   761   100.0   24.376   <0.6     CPM   43   97.7   245   77.5   358   89.3   646   84.9     CPM   1   2.3   69   21.8   42   10.5   112   14.7     Unknown   0   0.0   0   0.3   1   0.2   2   0.3     Total   44   100.0   316   100.0   401   100.0   761   100.0   24.376   <0.6     Reconstruction after CPM (n = 112)     No immediate reconstruction   1   100.0   19   27.5   18   42.9   38   33.9     Immediate reconstruction   1   100.0   69   100.0   42   100.0   112   100.0   4.699   0.0     Total   1   100.0   69   100.0   42   100.0   112   100.0   4.699   0.0     Total   1   100.0   69   100.0   42   100.0   112   100.0   4.699   0.0     Total   1   100.0   69   100.0   42   100.0   112   100.0   4.699   0.0     Total   1   100.0   69   100.0   42   100.0   112   100.0	Initial breast conservation type										
Wide excision and local flap         0         0.0         3         0.5         4         0.6         7         0.5           Unknown         0         0.0         2         0.3         2         0.3         3         0.2           Total         103         100.0         628         100.0         700         100.0         1431         100.0         3.322         0.5           Re-excision after breast conservation         Yes         21         20.4         113         18.0         124         17.7         258         18.0         No         8.0         79.6         506         80.7         567         80.9         1155         80.7         Unknown         0         0.0         8         1.3         10         1.4         18         1.3         17.1         100.0         0.391         0.8           Final operation         8         79.6         68.3         579         64.8         648         61.5         1322         63.5         40.8         64.8         648         61.5         1322         63.5         63.5         Mastectomy         44         31.7         31.4         35.1         400         38.0         758         36.5         10.1		98	95.1	558	88.9	633	90.4	1289	90.3		
Unknown         0         0.0         2         0.3         2         0.3         3         0.2         100.0         3.322         0.5           Re-excision after breast conservation         Yes         21         20.4         113         18.0         124         17.7         258         18.0         No         82         79.6         506         80.7         567         80.9         1155         80.7         0.0         1155         80.7         0.0         80.7         100.0         701         100.0         1431         100.0         0.391         0.8         80.7         100.0         701         100.0         1431         100.0         0.391         0.8         100.0         100.0         1431         100.0         0.391         0.8         100.0         100.0         0.391         0.8         100.0         100.0         100.0         0.391         0.8         100.0         0.391         0.8         1150         100.0         0.391         0.8         100.0         0.391         0.8         100.0         0.391         0.8         100.0         0.391         0.8         100.0         0.301         0.0         0.0         0.0         0.0         0.0         0.0         0.0	Therapeutic mammaplasty	6	5.8	65	10.2	61	8.7	132	9.2		
Total 103 100.0 628 100.0 700 100.0 1431 100.0 3.322 0.55 Re-excision after breast conservation  Yes 21 20.4 113 18.0 124 17.7 258 18.0 No 82 79.6 506 80.7 567 80.9 1155 80.7 Unknown 0 0.0 8 1.3 10 1.4 18 1.3 Total 100.0 100.0 627 100.0 701 100.0 1431 100.0 0.391 0.55 Mastectomy 44 31.7 314 35.1 400 38.0 758 36.5 Unknown 0 0.0 1 0.1 5 0.5 6 0.3 Total 139 100.0 894 100.0 1053 100.0 2086 100.0 3.615 0.1 Reconstruction after mastectomy No immediate reconstruction 13 29.5 151 47.8 130 32.2 294 38.3 Unknown 0 0.0 0 0 0.0 0 0.0 0 0.0 0 0.0 100.0 761 100.0 18.927 <0.0 CPM (unilateral cancer undergoing ipsilateral mastectomy)  No CPM 43 97.7 245 77.5 358 89.3 646 84.9 CPM (n = 112) No immediate reconstruction 1 1 00.0 316 100.0 401 100.0 761 100.0 24.376 <0.0 Reconstruction after CPM (n = 112) No immediate reconstruction 1 1 100.0 19 27.5 18 42.9 38 33.9 Immediate reconstruction 1 1 100.0 19 27.5 24 57.1 74 66.1 Unknown 0 0 0.0 0 0 0.0 0 0.0 0 0.0 0 0.0 Total 44 100.0 316 100.0 401 100.0 761 100.0 24.376 <0.0 Reconstruction after CPM (n = 112) No immediate reconstruction 1 1 100.0 19 27.5 18 42.9 38 33.9 Immediate reconstruction 0 0 0.0 50 72.5 24 57.1 74 66.1 Unknown 0 0 0.0 0 0 0.0 0 0.0 0 0.0 0 0.0 0.0	Wide excision and local flap	0	0.0	3	0.5	4	0.6	7	0.5		
Re-excision after breast conservation   Yes   21   20.4   113   18.0   124   17.7   258   18.0   No   82   79.6   506   80.7   567   80.9   1155   80.7   Unknown   0   0.0   8   1.3   10   1.4   18   1.3   10   1.4   18   1.3   10   1.4   18   1.3   10   1.4   18   1.3   10   1.4   18   1.3   10   1.4   18   1.3   10   1.4   18   1.3   10   1.4   18   1.3   10   1.4   18   1.3   10   1.4   18   1.3   10   1.4   18   1.3   10   1.4   18   1.3   10   1.4   18   1.3   10   1.4   18   1.3   10   1.4   18   1.3   1.4   10   1.4   18   1.3   1.4   10   1.4   18   1.3   1.4   10   1.4   18   1.3   1.4   10   1.4   18   1.3   1.4   10   1.4   18   1.3   1.4   10   1.4   18   1.3   1.4   10   1.4   18   1.3   1.4   10   1.4   18   1.3   1.4   10   1.4   18   1.3   1.4   10   1.4   18   1.3   1.4   10   1.4   18   1.3   1.4   10   1.4   18   1.3   1.4   10   1.4   18   1.3   1.4   10   1.4   18   1.3   1.4   10   1.4	Unknown	0	0.0	2	0.3	2	0.3	3	0.2		
Re-excision after breast conservation   Yes   21   20.4   113   18.0   124   17.7   258   18.0   No   82   79.6   506   80.7   567   80.9   1155   80.7   Unknown   0   0.0   8   1.3   10   1.4   18   1.3   10   1.4   18   1.3   10   1.4   18   1.3   10   1.4   18   1.3   10   1.4   18   1.3   10   1.4   18   1.3   10   1.4   18   1.3   10   1.4   18   1.3   10   1.4   18   1.3   10   1.4   18   1.3   10   1.4   18   1.3   10   1.4   18   1.3   10   1.4   18   1.3   10   1.4   18   1.3   10   1.4   18   1.3   1.4   10   1.4   18   1.3   1.4   10   1.4   18   1.3   1.4   10   1.4   18   1.3   1.4   10   1.4   18   1.3   1.4   10   1.4   18   1.3   1.4   10   1.4   18   1.3   1.4   10   1.4   18   1.3   1.4   10   1.4   18   1.3   1.4   10   1.4   18   1.3   1.4   10   1.4   18   1.3   1.4   10   1.4   18   1.3   1.4   10   1.4   18   1.3   1.4   10   1.4   18   1.3   1.4   10   1.4   18   1.3   1.4   10   1.4										3.322	0.50
No	Re-excision after breast conservative										
Unknown         0         0.0         8         1.3         10         1.4         18         1.3           Total         103         100.0         627         100.0         701         100.0         1431         100.0         0.391         0.8           Final operation         Breast conservation         95         68.3         579         64.8         648         61.5         1322         63.5         63.5         Mastectomy         44         31.7         314         35.1         400         38.0         758         36.5         0.3         Total         35.1         400         38.0         758         36.5         0.3         Total         31.7         314         35.1         400         38.0         758         36.5         0.3         Total         31.7         31.4         35.1         400         38.0         758         36.5         0.3         Total         31.7         31.7         31.4         35.1         400         38.0         758         36.5         0.3         100.0         2086         100.0         3.615         0.1         100.0         36.1         100.0         36.1         100.0         36.1         100.0         36.1         100.0	Yes	21	20.4	113	18.0	124	17.7	258	18.0		
Total         103         100.0         627         100.0         701         100.0         1431         100.0         0.391         0.8           Final operation         Breast conservation         95         68.3         579         64.8         648         61.5         1322         63.5         Mastectomy         44         31.7         314         35.1         400         38.0         758         36.5         Unknown         0         0.0         1         0.1         5         0.5         6         0.3         0.1         10.1         5         0.5         6         0.3         0.1         0.1         0.0	No	82	79.6	506	80.7	567	80.9	1155	80.7		
Final operation  Breast conservation 95 68.3 579 64.8 648 61.5 1322 63.5  Mastectomy 44 31.7 314 35.1 400 38.0 758 36.5  Unknown 0 0.0 1 0.1 5 0.5 6 0.3  Total 139 100.0 894 100.0 1053 100.0 2086 100.0 3.615 0.1  Reconstruction after mastectomy  No immediate reconstruction 31 70.5 165 52.2 271 67.8 467 61.7  Immediate reconstruction 13 29.5 151 47.8 130 32.2 294 38.3  Unknown 0 0.0 0 0.0 0 0.0 0 0.0 0.0  Total 44 100.0 316 100.0 401 100.0 761 100.0 18.927 <0.6  CPM (unilateral cancer undergoing ipsilateral mastectomy)  No CPM 43 97.7 245 77.5 358 89.3 646 84.9  CPM 1 2.3 69 21.8 42 10.5 112 14.7  Unknown 0 0.0 1 0.3 1 0.2 2 0.3  Total 44 100.0 316 100.0 401 100.0 761 100.0 24.376 <0.6  Reconstruction after CPM (n = 112)  No immediate reconstruction 1 100.0 19 27.5 18 42.9 38 33.9  Immediate reconstruction 0 0.0 0.0 0.0 0.0 0.0 0.0 0.0  Total 1 100.0 69 100.0 42 100.0 112 100.0 4.699 0.6	Unknown	0	0.0	8	1.3	10	1.4	18	1.3		
Final operation  Breast conservation 95 68.3 579 64.8 648 61.5 1322 63.5  Mastectomy 44 31.7 314 35.1 400 38.0 758 36.5  Unknown 0 0.0 1 0.1 5 0.5 6 0.3  Total 139 100.0 894 100.0 1053 100.0 2086 100.0 3.615 0.1  Reconstruction after mastectomy  No immediate reconstruction 31 70.5 165 52.2 271 67.8 467 61.7  Immediate reconstruction 13 29.5 151 47.8 130 32.2 294 38.3  Unknown 0 0.0 0 0.0 0 0.0 0 0.0 0.0  Total 44 100.0 316 100.0 401 100.0 761 100.0 18.927 <0.6  CPM (unilateral cancer undergoing ipsilateral mastectomy)  No CPM 43 97.7 245 77.5 358 89.3 646 84.9  CPM 1 2.3 69 21.8 42 10.5 112 14.7  Unknown 0 0.0 1 0.3 1 0.2 2 0.3  Total 44 100.0 316 100.0 401 100.0 761 100.0 24.376 <0.6  Reconstruction after CPM (n = 112)  No immediate reconstruction 1 100.0 19 27.5 18 42.9 38 33.9  Immediate reconstruction 0 0.0 0.0 0.0 0.0 0.0 0.0 0.0  Total 1 100.0 69 100.0 42 100.0 112 100.0 4.699 0.6										0.391	0.82
Breast conservation   95   68.3   579   64.8   648   61.5   1322   63.5     Mastectomy   44   31.7   314   35.1   400   38.0   758   36.5     Unknown   0   0.0   1   0.1   5   0.5   6   0.3     Total   139   100.0   894   100.0   1053   100.0   2086   100.0   3.615   0.1     Reconstruction after mastectomy   No immediate reconstruction   31   70.5   165   52.2   271   67.8   467   61.7     Immediate reconstruction   13   29.5   151   47.8   130   32.2   294   38.3     Unknown   0   0.0   0   0.0   0   0.0   0   0.0     Total   44   100.0   316   100.0   401   100.0   761   100.0   18.927   <0.0     CPM (unilateral cancer undergoing ipsilateral mastectomy)   No CPM   43   97.7   245   77.5   358   89.3   646   84.9     CPM   1   2.3   69   21.8   42   10.5   112   14.7     Unknown   0   0.0   1   0.3   1   0.2   2   0.3     Total   44   100.0   316   100.0   401   100.0   761   100.0   24.376   <0.0     Reconstruction after CPM (n = 112)   No immediate reconstruction   1   100.0   50   72.5   24   57.1   74   66.1     Unknown   0   0.0   0   0.0   0   0.0   0   0.0     Total   1   100.0   69   100.0   42   100.0   112   100.0   4.699   0.0     Total   1   100.0   69   100.0   42   100.0   112   100.0   4.699   0.0     Total   1   100.0   69   100.0   42   100.0   112   100.0   4.699   0.0     Total   1   100.0   69   100.0   42   100.0   112   100.0   4.699   0.0     Total   1   100.0   69   100.0   42   100.0   112   100.0   4.699   0.0     Total   1   100.0   69   100.0   42   100.0   112   100.0   4.699   0.0     Total   1   100.0   69   100.0   42   100.0   112   100.0   4.699   0.0     Total   1   100.0   69   100.0   42   100.0   112   100.0   4.699   0.0     Total   1   100.0   69   100.0   42   100.0   112   100.0   4.699   0.0     Total   1   100.0   69   100.0   42   100.0   112   100.0   4.699   0.0     Total   1   100.0   100	Final operation										
Unknown		95	68.3	579	64.8	648	61.5	1322	63.5		
Unknown         0         0.0         1         0.1         5         0.5         6         0.3           Total         139         100.0         894         100.0         1053         100.0         2086         100.0         3.615         0.1           Reconstruction after mastectomy         No immediate reconstruction         31         70.5         165         52.2         271         67.8         467         61.7           Immediate reconstruction         13         29.5         151         47.8         130         32.2         294         38.3           Unknown         0         0.0         0         0.0         0         0.0         0         0.0           Total         44         100.0         316         100.0         401         100.0         761         100.0         18.927         <0.0											
Total         139         100.0         894         100.0         1053         100.0         2086         100.0         3.615         0.1           Reconstruction after mastectomy         No immediate reconstruction         31         70.5         165         52.2         271         67.8         467         61.7           Immediate reconstruction         13         29.5         151         47.8         130         32.2         294         38.3           Unknown         0         0.0         0         0.0         0         0.0         0         0.0           Total         44         100.0         316         100.0         401         100.0         761         100.0         18.927         <0.0											
Reconstruction after mastectomy   No immediate reconstruction   31   70.5   165   52.2   271   67.8   467   61.7		139				1053				3.615	0.16
No immediate reconstruction 31 70.5 165 52.2 271 67.8 467 61.7 Immediate reconstruction 13 29.5 151 47.8 130 32.2 294 38.3 Unknown 0 0.0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 Total 44 100.0 316 100.0 401 100.0 761 100.0 18.927 <0.0 CPM (unilateral cancer undergoing ipsilateral mastectomy)  No CPM 43 97.7 245 77.5 358 89.3 646 84.9 CPM 1 2.3 69 21.8 42 10.5 112 14.7 Unknown 0 0.0 1 0.3 1 0.2 2 0.3 Total 44 100.0 316 100.0 401 100.0 761 100.0 24.376 <0.0 Reconstruction after CPM (n = 112)  No immediate reconstruction 1 100.0 19 27.5 18 42.9 38 33.9 Immediate reconstruction 0 0.0 50 72.5 24 57.1 74 66.1 Unknown 0 0.0 0.0 0 0.0 0 0.0 0 0.0 Total 1 100.0 69 100.0 42 100.0 112 100.0 4.699 0.0	Reconstruction after mastectomy										
Immediate reconstruction   13   29.5   151   47.8   130   32.2   294   38.3   2		31	70.5	165	52.2	271	67.8	467	61.7		
Unknown         0         0.0         0         0.0         0         0.0         0         0.0         0         0.0         0         0.0         0         0.0         0         0.0         0         0.0         0         0.0         0         0.0         0         0.0         0         0.0         0         0.0         0         0.0											
Total         44         100.0         316         100.0         401         100.0         761         100.0         18.927         < 0.0           CPM (unilateral cancer undergoing ipsilateral mastectomy)         No CPM         43         97.7         245         77.5         358         89.3         646         84.9           CPM         1         2.3         69         21.8         42         10.5         112         14.7           Unknown         0         0.0         1         0.3         1         0.2         2         0.3           Total         44         100.0         316         100.0         401         100.0         761         100.0         24.376         <0.0											
CPM (unilateral cancer undergoing ipsilateral mastectomy)  No CPM	Total	44	100.0			401	100.0	761		18.927	< 0.00
No CPM         43         97.7         245         77.5         358         89.3         646         84.9           CPM         1         2.3         69         21.8         42         10.5         112         14.7           Unknown         0         0.0         1         0.3         1         0.2         2         0.3           Total         44         100.0         316         100.0         401         100.0         761         100.0         24.376         <0.0	CPM (unilateral cancer undergoing	ipsilatera									
CPM         1         2.3         69         21.8         42         10.5         112         14.7           Unknown         0         0.0         1         0.3         1         0.2         2         0.3           Total         44         100.0         316         100.0         401         100.0         761         100.0         24.376         <0.0					77.5	358	89.3	646	84.9		
Unknown         0         0.0         1         0.3         1         0.2         2         0.3           Total         44         100.0         316         100.0         401         100.0         761         100.0         24.376         <0.0	CPM		2.3					112			
Total         44         100.0         316         100.0         401         100.0         761         100.0         24.376         < 0.0           Reconstruction after CPM (n = 112)         No immediate reconstruction         1         100.0         19         27.5         18         42.9         38         33.9           Immediate reconstruction         0         0.0         50         72.5         24         57.1         74         66.1           Unknown         0         0.0         0         0.0         0         0.0         0         0.0           Total         1         100.0         69         100.0         42         100.0         112         100.0         4.699         0.0	Unknown	0						2			
Reconstruction after CPM (n = 112)         No immediate reconstruction       1       100.0       19       27.5       18       42.9       38       33.9         Immediate reconstruction       0       0.0       50       72.5       24       57.1       74       66.1         Unknown       0       0.0       0       0.0       0       0.0       0       0.0         Total       1       100.0       69       100.0       42       100.0       112       100.0       4.699       0.0	Total	44		316		401		761		24.376	< 0.00
No immediate reconstruction         1         100.0         19         27.5         18         42.9         38         33.9           Immediate reconstruction         0         0.0         50         72.5         24         57.1         74         66.1           Unknown         0         0.0         0         0.0         0         0.0         0           Total         1         100.0         69         100.0         42         100.0         112         100.0         4.699         0.0	Reconstruction after CPM ( $n = 112$	2)									
Immediate reconstruction         0         0.0         50         72.5         24         57.1         74         66.1           Unknown         0         0.0         0         0.0         0         0.0         0         0.0           Total         1         100.0         69         100.0         42         100.0         112         100.0         4.699         0.0	The state of the s	•	100.0	19	27.5	18	42.9	38	33.9		
Unknown         0         0.0         0         0.0         0         0.0         0         0.0           Total         1         100.0         69         100.0         42         100.0         112         100.0         4.699         0.0											
Total 1 100.0 69 100.0 42 100.0 112 100.0 4.699 0.0											
										4.699	0.09
	0014										

6 Heilat *et al.* 

expected for a higher proportion of cancers present outside of the screening setting. These may represent cases of mass-forming, symptomatic DCIS; however, this is a relatively uncommon presentation and would not be expected to fully explain this finding. No previous studies reporting a high rate of DCIS in these women have been identified.

Women born in Arabic-speaking countries who developed invasive breast cancer had a higher rate (approximately double) of high-grade and HER2-positive breast cancers than the other groups (P=0.025). This has not been demonstrated in previous studies. A study examining data similar to the present study showed no difference in ER/PR and HER2-positive rates for Arab-born women living in the USA compared to the general population. The higher rate of HER2 positivity in this study means that these women are more likely to have chemotherapy and HER2-blocking treatment. This population is therefore likely to require additional support during treatment to cope with side effects (including menopause and fertility issues) compared to Australian-born women who may be less likely to require chemotherapy.

The slightly younger age and the pre-menopausal status of the women born in Arabic-speaking countries put them at higher risk for cancer-related distress. <sup>10</sup> Previous studies have shown that pre-menopausal breast cancer survivors tend to have poorer quality of life than older women, predominantly due to the side effects of chemotherapy and/or endocrine therapy that may cause menopausal or other hormonal symptoms. <sup>10,11</sup> Fertility concerns may also be relevant in this younger population. It is essential, therefore, that services are planned to address potential unmet needs for these women. Previous research in Australian migrant groups show that migrant cancer survivors have a higher number of unmet needs than their Australian-born counterparts. <sup>12,13</sup> Patient-reported outcome (PRO) measures were not included in this study but would provide valuable insight.

In this study, the mastectomy rate was not significantly different between Arab women and Australian-born women. However, women born in Arabic-speaking countries were less likely than Australian-born women to have immediate breast reconstruction after mastectomy (30% versus 48%). It should be noted that these rates refer to 'all comers' and do not exclude older women, those with comorbidities or advanced tumours or women considered medically unfit for breast reconstruction. The reasons for the difference between groups are unclear and require further evaluation. It is possible that there are cultural reasons for choosing against reconstruction. It is also possible that challenges in communicating with non-English-speaking women are a factor. Another explanation may be the higher disadvantage found in women from Arabicspeaking countries. Such disadvantage has been associated with not receiving breast reconstruction in the USA<sup>14</sup> and it may be related to the difficulties taking time away from essential work and family duties as well as other costs. Despite this, the 30% rate of reconstruction still compares favourably with the overall reported reconstruction rate of 18% in Australia. 15 It is also noted that the reconstruction rate in Australian-born women is more than three times higher than the national rate, a high comparator. The surgical unit has a strong commitment to breast reconstruction and most surgeons are trained in oncoplastic procedures and also have strong ties with plastic and reconstructive surgeons to offer the full range of reconstruction options. As not all women will choose or be medically suitable for immediate breast reconstruction, it is estimated that around 50% will take up the option when it is available 16 and the rate in Australian-born women approaches this estimate. Given the proven quality of life benefits to reconstruction for women who choose it, 17,18 it is essential that women have the opportunity for a balanced discussion about breast reconstruction when mastectomy is needed or chosen. This study demonstrates that informed discussion, appropriate counselling and access to reconstruction can occur in an ethnically diverse population where many consultations are conducted via health interpreters. It is clinic policy for patients who do not speak English to have a health interpreter present in the consultation. There are also occasions when there may be an Arabicspeaking doctor rotating through the clinic as a surgical fellow or registrar.

This study has several limitations. The non-Australian-born comparator group was extremely heterogeneous, which may limit conclusions about this group. Data were missing for some variables that has an unknown effect on conclusions. Many women had limited English and may have had difficulty providing accurate and comprehensive background information at the time of their presentation. In addition, adjuvant treatment data for chemotherapy (including neoadjuvant chemotherapy), radiotherapy and endocrine therapy were not available. PROs were not included in this study so the impact of the findings of younger age and HER2 positivity is not known. PRO is planned for future research in this population.

This study explored diagnosis, tumour and surgical treatment factors in women born in Arabic-speaking countries treated for breast cancer in Australia. Tumour and patient factors (high-grade, HER2-positive tumours in pre-menopausal women) indicated that a recommendation for chemotherapy is more likely in these women and this has implications for supportive care. Women from an Arab background may be at higher risk of unmet needs and this could be explored in future research. Increasing the participation rate in the national mammography screening programme for these ethnically diverse women may reduce this by increasing early detection.

Australian-born women were more likely to undergo breast reconstruction after mastectomy than women born in Arabic-speaking countries; however, the breast reconstruction rate of 30% in migrant women was much higher than the overall Australian rate of 18%.

#### **Conflicts of interest**

None declared.

#### References

- Australian Institute of Health and Welfare. Cancer in Australia 2017. 2017.
- World Health Organization. Cancer country profiles 2014. [Cited Jan 2019.] Available from URL: https://www.who.int/cancer/countryprofiles/en/#J
- Australian Institute of Health and Welfare. BreastScreen Australia monitoring report 2018. 2018.

- Westmead Breast Cancer Institute. Engaging Arabic speaking communities for BreastScreen. Available from URL: https://www.bci.org.au/ news/engaging-arabic-speaking-communities-breastscreen/
- Kwok C, Endrawes G, Lee CF. Cultural beliefs and attitudes about breast cancer and screening practices among Arabic women in Australia. Cancer Nurs. 2016; 39: 367–74.
- Western Sydney Regional Organisation of Councils. Community profile 2016. [Cited Jun 2018.] Available from URL: https://profile.id.com.au/ wsrcc
- Australian Bureau of Statistics. Socio-economic indexes for areas (SEIFA). 2013.
- Runnak MA, Hazha MA, Hemin HA, Wasan AA, Rekawt RM, Michael HD. A population-based study of Kurdish breast cancer in northern Iraq: hormone receptor and HER2 status. A comparison with Arabic women and United States SEER data. BMC Womens Health 2012; 12: 16.
- El Saghir NS, Khalil MK, Eid T et al. Trends in epidemiology and management of breast cancer in developing Arab countries: a literature and registry analysis. Int. J. Surg. 2007; 5: 225–33.
- Howard-Anderson J, Ganz PA, Bower JE, Stanton AL. Quality of life, fertility concerns, and behavioral health outcomes in younger breast cancer survivors: a systematic review. J. Natl. Cancer Inst. 2012; 104: 186–405.
- Brennan ME, Boyle FM, Butow PN, Spillane AJ. Evaluation of a survivorship care plan: long-term use, care coordination and quality of life in breast cancer survivors. *Breast Cancer Manag.* 2015; 4: 145–57.
- Sze M, Butow P, Bell M et al. Migrant health in cancer: outcome disparities and the determinant role of migrant-specific variables. Oncologist 2015; 20: 523–31.

- Butow PN, Bell ML, Aldridge LJ et al. Unmet needs in immigrant cancer survivors: a cross-sectional population-based study. Support. Care Cancer 2013; 21: 2509–20.
- Sergesketter AR, Thomas SM, Lane WO et al. Decline in racial disparities in postmastectomy breast reconstruction: a Surveillance, Epidemiology, and End Results analysis from 1998 to 2014. Plast. Reconstr. Surg. 2019; 143: 1560–70.
- Flitcroft K, Brennan ME, Costa D, Spillane A. Documenting patterns of breast reconstruction in Australia: the national picture. *Breast* 2016; 30: 47–53.
- Brennan ME, Spillane AJ. Uptake and predictors of post-mastectomy reconstruction in women with breast malignancy – systematic review. Eur. J. Surg. Oncol. 2013; 39: 527–41.
- Chen W, Lv X, Xu X, Gao X, Wang B. Meta-analysis for psychological impact of breast reconstruction in patients with breast cancer. *Breast Cancer* 2018; 25: 464–9.
- Fanakidou I, Zyga S, Alikari V, Tsironi M, Stathoulis J, Theofilou P. Mental health, loneliness, and illness perception outcomes in quality of life among young breast cancer patients after mastectomy: the role of breast reconstruction. *Qual. Life Res.* 2018; 27: 539–43.

#### **Supporting information**

Additional Supporting Information may be found in the online version of this article at the publisher's web-site:

**Table S1.** Country of birth of women treated for ductal carcinoma in situ or invasive breast cancer between 2011 and 2017.

**Table S2.** Additional demographic data for women born in Arab countries, Australia and other countries.